Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: APGE

Apogee Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for APGE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Apogee Therapeutics, Inc. (NASDAQ: APGE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 03:54 UTC.

What Apogee Therapeutics, Inc. does

Apogee Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody treatments for inflammatory and immunology conditions including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company's pipeline includes multiple antibody programs built on four validated targets, designed as both standalone therapies and combination treatments.

Summarized from Apogee Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

APGE no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.

Key facts

Charts

Charts are in the appInteractive charts for APGE are available in Oxford Ledge.
Open APGE in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-03
  • 2026-09-03DirectorStock Option (Right to Buy)Returned to company-14,461—
  • 2026-09-03DirectorStock Option (Right to Buy)Returned to company-7,657—
  • 2026-09-03DirectorNon-Voting Common StockReturned to company-6,743,321$911.09M
Sign in to see all transactions →

Company news

View all →
For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for APGE and 5,000+ tickers.

Create a free account — keep APGE
For your agent
GET /api/data?ticker=APGE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt